Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04253236 · ClinicalTrials.gov registry record · Phase 2
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).
A Phase 2 study, sponsored by Immunovant Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04253236 is a Phase 2 study that was terminated before completion, run by Immunovant Sciences. The registered enrollment target is 5 participants.
The verdict
NCT04253236, a Phase 2 study, was terminated before completion, sponsored by Immunovant Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase 2 non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 in patients with Warm Autoimmune Hemolytic Anemia.
Interventions
- DRUG RVT-1401 680 mg/weekly
- DRUG RVT-1401 340 mg/weekly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-08-11 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04253236
The ClinicalTrials.gov registry entry for NCT04253236 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunovant Sciences, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RVT-1401 680 mg/weekly is the first listed.
NCT04253236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04253236 about?
NCT04253236 is a clinical study titled "To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).". This is a Phase 2 non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 in patients with Warm Autoimmune Hemolytic Anemia.
What is the current status of trial NCT04253236?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-08-11. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT04253236?
The interventions under investigation include: RVT-1401 680 mg/weekly (DRUG), RVT-1401 340 mg/weekly (DRUG).
Who is sponsoring clinical trial NCT04253236?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.